R. Roagna

发表

Sentinel Lymph Node and Breast Cancer Staging: Final Results of the Turin Multicenter Study

P. Sismondi, M. Massobrio, G. Bisi, 2000, Tumori.

Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.

P. Sismondi, R. Ponzone, M. De Bortoli, 1994, Anticancer research.

Hormone replacement therapy in cancer survivors.

P. Sismondi, N. Biglia, R. Ponzone, 2004, Maturitas.

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.

F. Boccardo, A. Rubagotti, L. Orzalesi, 2013, European journal of cancer.

Menopause after breast cancer: a survey on breast cancer survivors.

P. Sismondi, N. Biglia, R. Ponzone, 2003, Maturitas.

Hormone Replacement Therapy and Breast Cancer Risk in High-Risk Subgroups

P. Sismondi, N. Biglia, R. Ponzone, 1999 .

How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative?

P. Sismondi, N. Biglia, R. Ponzone, 2000, European journal of cancer.

Prostate-specific antigen in serum of women with breast cancer.

D. Katsaros, E. Diamandis, R. Ponzone, 1995, British Journal of Cancer.

Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases.

E. Diamandis, G. Tomlinson, R. Ponzone, 1997, British Journal of Cancer.

Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.

P. Sismondi, C. López-Otín, A. Scorilas, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.

P. Sismondi, D. Katsaros, E. Diamandis, 1995, Cancer research.

Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.

P. Sismondi, N. Biglia, R. Ponzone, 2005, Maturitas.

Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis

P. Sismondi, N. Biglia, G. Yousef, 2002, British Journal of Cancer.

IMMUNOFLUOROMETRICALLY DETERMINED p 53 ACCUMULATION AS A PROGNOSTIC INDICATOR IN ITALIAN BREAST CANCER PATIENTS

P. Sismondi, D. Katsaros, E. Diamandis, 1998 .

The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer

P. Sismondi, N. Biglia, G. Yousef, 2003, Breast Cancer Research and Treatment.

Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.

P. Sismondi, N. Biglia, G. Yousef, 2002, Clinical chemistry.

HRT, breast and endometrial cancers: strategies and intervention options.

C. Campagnoli, P. Sismondi, N. Biglia, 1999, Maturitas.

TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.

P. Sismondi, N. Biglia, R. Ponzone, 1996, Anticancer research.

Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients.

P. Sismondi, D. Katsaros, E. Diamandis, 1996, British Journal of Cancer.

Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification.

E. Diamandis, R. Ponzone, H. Yu, 1999, Clinical biochemistry.

Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue

P. Sismondi, C. Croce, E. Diamandis, 2005, Breast Cancer Research and Treatment.

Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease

E. Diamandis, G. Tomlinson, R. Ponzone, 1999, Journal of clinical laboratory analysis.